1887

Abstract

Epstein–Barr virus (EBV) latent membrane protein 2A (LMP2A) blocks B-cell receptor (BCR) signalling after BCR cross-linking to inhibit activation of lytic EBV, and ectopically expressed LMP2B negatively regulates LMP2A. Here, it is demonstrated that silencing of in EBV-harbouring Burkitt's lymphoma Akata cells results in reduced expression of EBV immediate-early lytic gene mRNA and late lytic gp350/220 protein upon BCR cross-linking. Similarly, reduction of lytic EBV activation was observed in Akata cells overexpressing LMP2A. In contrast, silencing of expression resulted in higher lytic EBV mRNA and protein expression in BCR cross-linked Akata cells. These observations indicate a role for LMP2B distinct from that of LMP2A in regulation of lytic EBV activation in the host cell and support the hypothesis that LMP2B exhibits a negative-regulatory effect on the ability of LMP2A to maintain EBV latency by preventing the switch to lytic replication.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.82790-0
2007-05-01
2020-10-28
Loading full text...

Full text loading...

/deliver/fulltext/jgv/88/5/1454.html?itemId=/content/journal/jgv/10.1099/vir.0.82790-0&mimeType=html&fmt=ahah

References

  1. Allen M. D., Young L. S., Dawson C. W. 2005; The Epstein-Barr virus-encoded LMP2A and LMP2B proteins promote epithelial cell spreading and motility. J Virol 79:1789–1802 [CrossRef]
    [Google Scholar]
  2. Babcock G. J., Thorley-Lawson D. A. 2000; Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors. Proc Natl Acad Sci U S A 97:12250–12255 [CrossRef]
    [Google Scholar]
  3. Babcock G. J., Hochberg D., Thorley-Lawson A. D. 2000; The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13:497–506 [CrossRef]
    [Google Scholar]
  4. Bernasconi M., Berger C., Sigrist J. A., Bonanomi A., Sobek J., Niggli F. K., Nadal D. 2006; Quantitative profiling of housekeeping and Epstein-Barr virus gene transcription in Burkitt lymphoma cell lines using an oligonucleotide microarray. Virol J 3:43 [CrossRef]
    [Google Scholar]
  5. Caldwell R. G., Brown R. C., Longnecker R. 2000; Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice. J Virol 74:1101–1113 [CrossRef]
    [Google Scholar]
  6. Daibata M., Humphreys R. E., Takada K., Sairenji T. 1990; Activation of latent EBV via anti-IgG-triggered, second messenger pathways in the Burkitt's lymphoma cell line Akata. J Immunol 144:4788–4793
    [Google Scholar]
  7. Fruehling S., Longnecker R. 1997; The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction. Virology 235:241–251 [CrossRef]
    [Google Scholar]
  8. Fruehling S., Lee S. K., Herrold R., Frech B., Laux G., Kremmer E., Grasser F. A., Longnecker R. 1996; Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction. J Virol 70:6216–6226
    [Google Scholar]
  9. Fukuda M., Longnecker R. 2005; Epstein-Barr virus (EBV) latent membrane protein 2A regulates B-cell receptor-induced apoptosis and EBV reactivation through tyrosine phosphorylation. J Virol 79:8655–8660 [CrossRef]
    [Google Scholar]
  10. Graham F. L., Smiley J., Russell W. C., Nairn R. 1977; Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36:59–74 [CrossRef]
    [Google Scholar]
  11. Konishi K., Maruo S., Kato H., Takada K. 2001; Role of Epstein-Barr virus-encoded latent membrane protein 2A on virus-induced immortalization and virus activation. J Gen Virol 82:1451–1456
    [Google Scholar]
  12. Longnecker R., Druker B., Roberts T. M., Kieff E. 1991; An Epstein-Barr virus protein associated with cell growth transformation interacts with a tyrosine kinase. J Virol 65:3681–3692
    [Google Scholar]
  13. Longnecker R., Miller C. L., Miao X. Q., Marchini A., Kieff E. 1992; The only domain which distinguishes Epstein-Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro; LMP2A is therefore nonessential. J Virol 66:6461–6469
    [Google Scholar]
  14. Lynch D. T., Zimmerman J. S., Rowe D. T. 2002; Epstein-Barr virus latent membrane protein 2B (LMP2B) co-localizes with LMP2A in perinuclear regions in transiently transfected cells. J Gen Virol 83:1025–1035
    [Google Scholar]
  15. Mancao C., Altmann M., Jungnickel B., Hammerschmidt W. 2005; Rescue of ‘crippled’ germinal center B cells from apoptosis by Epstein-Barr virus. Blood 106:4339–4344 [CrossRef]
    [Google Scholar]
  16. Matskova L., Ernberg I., Pawson T., Winberg G. 2001; C-terminal domain of the Epstein-Barr virus LMP2A membrane protein contains a clustering signal. J Virol 75:10941–10949 [CrossRef]
    [Google Scholar]
  17. Merchant M., Caldwell R. G., Longnecker R. 2000; The LMP2A ITAM is essential for providing B cells with development and survival signals in vivo. J Virol 74:9115–9124 [CrossRef]
    [Google Scholar]
  18. Miller C. L., Lee J. H., Kieff E., Burkhardt A. L., Bolen J. B., Longnecker R. 1994a; Epstein-Barr virus protein LMP2A regulates reactivation from latency by negatively regulating tyrosine kinases involved in sIg-mediated signal transduction. Infect Agents Dis 3:128–136
    [Google Scholar]
  19. Miller C. L., Lee J. H., Kieff E., Longnecker R. 1994b; An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking. Proc Natl Acad Sci U S A 91:772–776 [CrossRef]
    [Google Scholar]
  20. Miller C. L., Burkhardt A. L., Lee J. H., Stealey B., Longnecker R., Bolen J. B., Kieff E. 1995; Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity 2:155–166 [CrossRef]
    [Google Scholar]
  21. Murray P. G., Young L. S. 2002; The role of the Epstein-Barr virus in human disease. Front Biosci 7:d519–d540 [CrossRef]
    [Google Scholar]
  22. Portis T., Cooper L., Dennis P., Longnecker R. 2002; The LMP2A signalosome – a therapeutic target for Epstein-Barr virus latency and associated disease. Front Biosci 7:d414–d426 [CrossRef]
    [Google Scholar]
  23. Portis T., Ikeda M., Longnecker R. 2004; Epstein-Barr virus LMP2A: regulating cellular ubiquitination processes for maintenance of viral latency?. Trends Immunol 25:422–426 [CrossRef]
    [Google Scholar]
  24. Rickinson A. B., Kieff E. 2001; Epstein-Barr Virus. In Fields Virology , 4th edn. pp 2575–2627 Edited by Knipe D. M., Howley P. M. Philadelphia, PA: Lippincott Williams & Wilkins;
    [Google Scholar]
  25. Rovedo M., Longnecker R. 2007; Epstein Barr virus latent membrane protein 2B (LMP2B) modulates LMP2A activity. J Virol 81:84–94 [CrossRef]
    [Google Scholar]
  26. Rowe D. T. 1999; Epstein-Barr virus immortalization and latency. Front Biosci 4:D346–D371 [CrossRef]
    [Google Scholar]
  27. Sample J., Liebowitz D., Kieff E. 1989; Two related Epstein-Barr virus membrane proteins are encoded by separate genes. J Virol 63:933–937
    [Google Scholar]
  28. Schaefer B. C., Mitchell T. C., Kappler J. W., Marrack P. 2001; A novel family of retroviral vectors for the rapid production of complex stable cell lines. Anal Biochem 297:86–93 [CrossRef]
    [Google Scholar]
  29. Speck P., Kline K. A., Cheresh P., Longnecker R. 1999; Epstein-Barr virus lacking latent membrane protein 2 immortalizes B cells with efficiency indistinguishable from that of wild-type virus. J Gen Virol 80:2193–2203
    [Google Scholar]
  30. Stewart S., Dawson C. W., Takada K., Curnow J., Moody C. A., Sixbey J. W., Young L. S. 2004; Epstein-Barr virus-encoded LMP2A regulates viral and cellular gene expression by modulation of the NF-kappaB transcription factor pathway. Proc Natl Acad Sci U S A 101:15730–15735 [CrossRef]
    [Google Scholar]
  31. Swart R., Ruf I. K., Sample J., Longnecker R. 2000; Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-kinase/Akt pathway. J Virol 74:10838–10845 [CrossRef]
    [Google Scholar]
  32. Takada K. 1984; Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines. Int J Cancer 33:27–32 [CrossRef]
    [Google Scholar]
  33. Tao Q., Robertson K. D., Manns A., Hildesheim A., Ambinder R. F. 1998; Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue. Blood 91:1373–1381
    [Google Scholar]
  34. Ventura A., Meissner A., Dillon C. P., McManus M., Sharp P. A., Van Parijs L., Jaenisch R., Jacks T. 2004; Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci U S A 101:10380–10385 [CrossRef]
    [Google Scholar]
  35. Young L. S., Murray P. G. 2003; Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 22:5108–5121 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.82790-0
Loading
/content/journal/jgv/10.1099/vir.0.82790-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error